Extended trading hours didn’t disappoint this week, with a mix of earnings beats, guidance letdowns, and a presidential mic-drop that sent obesity drug stocks wobbling. Let’s unpack the biggest after-hours movers and shakeups.
🚂 CSX Corporation: Chugging Along
CSX (CSX) shares climbed 2% after hours, thanks to a solid Q3 earnings beat. The railroad giant posted 44 cents per share on $3.59 billion in revenue, just edging past analyst expectations.
Sure, coal prices and merchandise volume dipped, but CSX still managed to keep its train on the tracks. Investors gave a thumbs-up to the company’s ability to deliver, even with a few bumps in the cargo hold.
💻 Interactive Brokers: Beat the Street, Still Got Beat
Interactive Brokers (IBKR) pulled off a double beat—57 cents EPS vs. 54 cents expected, and $1.61 billion in revenue vs. $1.52 billion forecast. Net interest income jumped 21%, driven by stronger securities lending and beefier margin loans.
And yet… the stock dropped nearly 3%. Wall Street’s mood? "Nice numbers, but we wanted fireworks." Sometimes even a clean earnings sheet isn’t enough to keep the party going.
☁️ Oracle: Big Talk, Small Reaction
Oracle (ORCL) dipped 2.4% after laying out its long-term vision at the AI World conference in Vegas. The company expects a 31% compound annual growth rate over the next five years and announced a cloud deal with Meta.
But investors weren’t exactly throwing confetti. Maybe it was the already seen of yet another AI pitch, or maybe Wall Street just wanted more immediate results. Either way, Oracle’s cloud forecast didn’t quite float.
🏦 Bank OZK: Ouch-ZK
Bank OZK (OZK) fell 3% after missing Q3 earnings expectations—$1.59 per share vs. $1.66 expected. That drop added to a 7% slide earlier in the week, as financial stocks took a hit over concerns about bad loans.
OZK’s California division is feeling the heat, and investors are clearly not in the mood for surprises. The bank’s earnings miss was the cherry on top of a rough week.
💊 Novo Nordisk & Eli Lilly: Presidential Whiplash
Shares of Novo Nordisk (NVO) and Eli Lilly (LLY) took a hit after President Donald Trump made waves during a fertility briefing, suggesting that obesity drug prices would be "much lower."
Cue the market jitters. Novo, maker of Wegovy and Ozempic, fell 3%, while Eli Lilly, behind Mounjaro and Zepbound, dropped 2%. Dr. Mehmet Oz, now head of CMS, clarified that pricing negotiations haven’t happened yet—but the damage was done.
Investors in GLP-1 stocks might want to buckle up—politics and pricing are about to get spicy.
The Bottom Line
From railroads that deliver to brokers that can’t catch a break, and from cloud optimism to pharma drama, this week’s after-hours action had a little bit of everything. Whether it’s earnings beats or presidential tweets, Wall Street’s after-dark moves are never boring.